Nobelitin and Sorafenib Combination Therapy
To enhance hepatocellular carcinoma (HCC) treatment, the combination of Nobelitin (NOB) and Sorafenib (SOR) is being explored. Nobelitin is utilized to induce the expression of BMAL1, a circadian rhythm-related protein, with the goal of improving the effectiveness of SOR in treating HCC. This innovative strategy holds promise for optimizing treatment outcomes for HCC patients. Overall design: To investigate the effects of NOB and SOR reatments on HCC, the HepG2 cancer cell line was treated with vehicle control, NOB alone, SOR alone, and a combination of NOB and SOR.